UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 121 - 135 of 671

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

AUA 2009 - The Leaky Bladder Post-Prostatectomy - SUFU Meeting - Session Highlights
Friday, 05 June 2009
CHICAGO, IL, USA (UroToday.com) - Incontinence After RRP – When It’s not the Sphincter
Login to read more...

Incidence of Overactive Bladder after Vaginal Hysterectomy and Associated Repairs for Pelvic Organ Prolapse - Abstract
Friday, 05 June 2009
Department of Obstetrics and Gynaecology, Hospital Donostia, San Sebastián, Spain.
read more

Bother Related to Bladder Control and Health Care Seeking Behavior in Adults in the United States - Abstract
Thursday, 04 June 2009
ValueMedics Research, L. L. C., Falls Church, Virginia, USA.
read more

Efficacy of Combined Amlodipine/Terazosin Therapy in Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-blind Clinical Trial - Abstract
Wednesday, 03 June 2009
University of Science and Technology of China School of Life Sciences, Hefei, Anhui, China.
read more

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study - Abstract
Tuesday, 02 June 2009
Medical University of South Carolina, Charleston, South Carolina, USA.
read more

Impact of Overactive Bladder on Work Productivity in the United States: Results from EpiLUTS - Abstract
Monday, 01 June 2009
Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Ave, Ste 600, Bethesda, MD 20814, USA.
read more

Interson Releases New USB Ultrasound Imaging Probes
Monday, 01 June 2009
PLEASANTON, CA, USA (Press Release) - May 29, 2009
read more

Naftopidil and Propiverine Hydrochloride for Treatment of Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Concomitant Overactive Bladder: A Prospective Randomized Controlled Study - Abstract
Friday, 29 May 2009
Department of Urology, Kawasaki Medical School, Kurashiki, Japan.
read more

Fesoterodine: A New Agent for Treating Overactive Bladder - Abstract
Friday, 29 May 2009
Brown University, 122 Shaw Ave, Cranston, RI 02905-3833, USA.
read more

Lower Urinary Tract Symptoms: Lack of Change in Prevalence and Help-Seeking Behaviour in Two Population-Based Surveys of Women in 1991 and 2007 - Abstract
Thursday, 28 May 2009
Department of Obstetrics and Gynaecology, Sahlgrenska Academy at Gothenburg University and Sahlgrenska University Hospital, Gothenburg, Sweden.
read more

Combined Effects of Behavioral Intervention and Tolterodine in Patients Dissatisfied With Overactive Bladder Medication - Abstract
Wednesday, 27 May 2009
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63141, USA.
read more

Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks - Abstract
Tuesday, 26 May 2009
Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
read more

Clean Intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections: Short-Term Effect on Quality of Life - Abstract
Monday, 25 May 2009
Department of Uro-Neurology, the National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, University College London Institute of Neurology, London, United Kingdom.
read more

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder - Abstract
Friday, 22 May 2009
Division of Urogynecology, Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York, USA.
read more

√ Editorial - Two Types of Urgency
Thursday, 21 May 2009
√ Editor's Pick: BERKELEY, CA (UroToday.com) - Urgency Is Not Just Urgency
Login to read more...

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder